This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

[video] Quick Take: Johnson & Johnson Has Healthy Quarter but Medical Tax Weighs

NEW YORK (TheStreet) -- Johnson & Johnson (JNJ) reported earnings that beat on top- and bottom-line estimates. 

TheStreet's Debra Borchardt noted that shares of JNJ initially rallied on the news but are currently lower by about 2%. The decline likely stems from management's full-year earnings guidance of $5.75 to $5.85. Analysts were expecting earnings per share of $5.85, she said. 

Tylenol, Motrin, Neutrogena, Aveeno and Listerine led Johnson & Johnson's U.S. consumer sales, while Remicade, Zytiga and Prezista led the company's pharmaceutical sales. 

Borchardt added that the company lost its exclusivity for Concerta, a drug for ADHD, but gained Food and Drug Administration approval for Olysio and Imbruvica.

The company is optimistic about its orthopedic business for replacement hips and knees; knee operations are up 8% from the previous year, she said.

Borchardt concluded that Johnson & Johnson did not appear to be very happy about the medical device tax under the Affordable Care Act, but was careful on the conference call not to say anything that could come back to bite the company later. 

-- Written by Bret Kenwell in Petoskey, Mich.

Bret Kenwell currently writes, blogs and also contributes to Robert Weinstein's Weekly Options Newsletter. Focuses on short-to-intermediate-term trading opportunities that can be exposed via options. He prefers to use debit trades on momentum setups and credit trades on support/resistance setups. He also focuses on building long-term wealth by searching for consistent, quality dividend paying companies and long-term growth companies. He considers himself the surfer, not the wave, in relation to the market and himself. He has no allegiance to either the bull side or the bear side.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
AAPL $125.80 0.00%
FB $77.56 0.00%
GOOG $530.80 0.00%
TSLA $232.95 0.00%
YHOO $41.30 0.00%

Markets

DOW 17,928.20 -142.20 -0.79%
S&P 500 2,089.46 -25.03 -1.18%
NASDAQ 4,939.3270 -77.6020 -1.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs